The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

This study has been completed.
Sponsor:
Collaborator:
Richmond Pharmacology Limited
Information provided by:
Evotec Neurosciences GmbH
ClinicalTrials.gov Identifier:
NCT00526968
First received: September 7, 2007
Last updated: February 14, 2008
Last verified: February 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2007
  Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)